P. Keller

发表

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.

N. Pryer, D. W. Fry, W. Elliott, 2004, Molecular cancer therapeutics.

TL1, a Novel Tumor Necrosis Factor-like Cytokine, Induces Apoptosis in Endothelial Cells

T. Yue, G. Feuerstein, Guo-liang Yu, 1999, The Journal of Biological Chemistry.

Cell Cycle and Biochemical Effects of PD 0183812

D. W. Fry, E. Dobrusin, W. Leopold, 2001, The Journal of Biological Chemistry.

Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.

D. W. Fry, D. Mcnamara, Hairong Zhou, 2005, Journal of medicinal chemistry.

Cell Cycle and Biochemical Effects of PD 0183812 A POTENT INHIBITOR OF THE CYCLIN D-DEPENDENT KINASES CDK4 AND CDK6*

D. W. Fry, E. Dobrusin, W. Leopold, 2001 .

Glucocorticoid and developmental regulation of amylase mRNAs in mouse liver cells

M. Meisler, P. Keller, G. Darlington, 1988 .

Glucocorticoid andDevelopmental Regulation ofAmylasemRNAs inMouseLiver Cells

P. Keller, G. Darlington, H. MEISLERl, 1988 .

Expression, purification and characterization of focal adhesion kinase using a baculovirus system.

D. W. Fry, P. Keller, B. E. Withers, 1996, Protein expression and purification.

Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.

W. Denny, A. Doherty, A. Bridges, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Amino‐terminal sequence determinants for substrate recognition by platelet‐derived growth factor receptor tyrosine kinase

W. Leopold, W. Miller, P. M. Chan, 1996, FEBS letters.

Glucocorticoid and developmental regulation of amylase mRNAs in mouse liver cells

M. Meisler, P. Keller, G. Darlington, 1988, Molecular and cellular biology.

Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.

D. W. Fry, W. Elliott, D. Mcnamara, 2005, Journal of medicinal chemistry.

Gestational zinc requirement of the A/J mouse: effects of a marginal zinc deficiency on in utero B-cell development

P. Fraker, P. Keller, 1986 .

Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis.

P. Keller, R. Sorenson, H. Showalter, 2011, Bioorganic & medicinal chemistry letters.

Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

B. Ross, A. Rehemtulla, T. Lawrence, 2012, Molecular Cancer Therapeutics.

Biochemical and antiproliferative properties of 4-[ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor.

W. Denny, G. Rewcastle, A. Bridges, 1997, Biochemical pharmacology.

Discovery of a series of 2-(1H-pyrazol-1-yl)pyridines as ALK5 inhibitors with potential utility in the prevention of dermal scarring.

Mostofa A Hena, B. Finzel, R. Gilbertsen, 2012, Bioorganic & medicinal chemistry letters.

2-Aminoquinazoline inhibitors of cyclin-dependent kinases.

D. W. Fry, E. Dobrusin, Y. Bathini, 2005, Bioorganic & medicinal chemistry letters.

Title : Co-Targeting MAPK and PI 3 K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer Running Title : MEK and Akt pathway radiosensitization in pancreatic cancer

B. Ross, A. Rehemtulla, T. Lawrence, 2012 .

Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor.

A. Doherty, R. Panek, G. Lu, 1997, Life sciences.